Cargando…

Predicting Response to Anthracyclines in Ovarian Cancer

(1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrero, Annamaria, Borghese, Martina, Restaino, Stefano, Puppo, Andrea, Vizzielli, Giuseppe, Biglia, Nicoletta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998349/
https://www.ncbi.nlm.nih.gov/pubmed/35409939
http://dx.doi.org/10.3390/ijerph19074260
_version_ 1784684921902596096
author Ferrero, Annamaria
Borghese, Martina
Restaino, Stefano
Puppo, Andrea
Vizzielli, Giuseppe
Biglia, Nicoletta
author_facet Ferrero, Annamaria
Borghese, Martina
Restaino, Stefano
Puppo, Andrea
Vizzielli, Giuseppe
Biglia, Nicoletta
author_sort Ferrero, Annamaria
collection PubMed
description (1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand–foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy.
format Online
Article
Text
id pubmed-8998349
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89983492022-04-12 Predicting Response to Anthracyclines in Ovarian Cancer Ferrero, Annamaria Borghese, Martina Restaino, Stefano Puppo, Andrea Vizzielli, Giuseppe Biglia, Nicoletta Int J Environ Res Public Health Review (1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand–foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy. MDPI 2022-04-02 /pmc/articles/PMC8998349/ /pubmed/35409939 http://dx.doi.org/10.3390/ijerph19074260 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ferrero, Annamaria
Borghese, Martina
Restaino, Stefano
Puppo, Andrea
Vizzielli, Giuseppe
Biglia, Nicoletta
Predicting Response to Anthracyclines in Ovarian Cancer
title Predicting Response to Anthracyclines in Ovarian Cancer
title_full Predicting Response to Anthracyclines in Ovarian Cancer
title_fullStr Predicting Response to Anthracyclines in Ovarian Cancer
title_full_unstemmed Predicting Response to Anthracyclines in Ovarian Cancer
title_short Predicting Response to Anthracyclines in Ovarian Cancer
title_sort predicting response to anthracyclines in ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998349/
https://www.ncbi.nlm.nih.gov/pubmed/35409939
http://dx.doi.org/10.3390/ijerph19074260
work_keys_str_mv AT ferreroannamaria predictingresponsetoanthracyclinesinovariancancer
AT borghesemartina predictingresponsetoanthracyclinesinovariancancer
AT restainostefano predictingresponsetoanthracyclinesinovariancancer
AT puppoandrea predictingresponsetoanthracyclinesinovariancancer
AT vizzielligiuseppe predictingresponsetoanthracyclinesinovariancancer
AT biglianicoletta predictingresponsetoanthracyclinesinovariancancer